SUMMARY Whole blood procoagulant activity was determined by measuring the recalcification time ofcitrated blood, with and without the addition of bacterial endotoxin, in patients with breast cancer (n = 39), colorectal cancer (n = 20), benign breast disease (n = 15), benign colorectal disease (n = 1 1), normal volunteers (n = 15) and inpatients with non-malignant disease (n = 22). The median clotting times of those samples incubated with endotoxin were significantly shorter in the patients with breast and colorectal cancer compared with normal controls. Furthermore, significant differences between the median clotting times of stimulated and unstimulated samples within each subject group were observed only in the two cancer groups. There was no correlation between whole blood procoagulant activity and absolute monocyte counts, with histological staging or with plasma concentrations of plasma fibrinopeptide A.
The increased incidence of clinical and laboratory abnormalities of haemostasis in malignant disease is well recognised,' and sensitive markers such as plasma fibrinopeptide A, often provide evidence of in vivo clotting activation in acute leukaemia23 and solid tumours.45 Although the mechanism of coagulation activation in cancer is probably multifactorial, procoagulants associated with tumours may have a role in this process. Various malignant tumours"7 and leukaemic promyelocytes8 may release tissue factor, and specific factor X activating tissue procoagulants occur in a wide range of malignancies in man and animals.9 1 ' Peripheral blood monocytes and tissue macrophages also express tissue factor, particularly after stimulation with endotoxin," 12 and this activity may be increased in both animal'3 and human'4 malignancies. Furthermore, the correlation between unstimulated monocyte tissue factor activity and plasma fibrinopeptide A in patients with advanced lung cancer suggests that monocyte tissue factor expression is related to the increased rate of fibrin generation in vivo. 4
Accepted for publication 12 December 1988 Most studies have measured tissue factor activity in isolated monocytes, although manipulation of the cells during this procedure may artefactually increase tissue factor production. '5 As monocytes are the only circulating blood cells capable of synthesising tissue factor, the shortening of the recalcification time of whole blood incubated with endotoxin may be attributed to an increase in monocyte tissue factor synthesis.'6 Using this principle, Dasmahapatra et al showed that the recalcification time was significantly shorter in patients with cancer compared with controls,'7 particularly in samples stimulated with endotoxin, and concluded that the test might distinguish such patients from both controls and subjects with benign tumours. Monocyte counts were not reported in this study, however, and the possibility that monocytosis in the cancer groups might have accounted for the increased procoagulant activity was not excluded. Plasma fibrinopeptide A concentrations were also not determined, and thus a possible correlation between monocyte tissue factor concentrations and ongoing intravascular coagulation was not assessed.
The (10 ml) was collected preoperatively using 21G butterfly needles; 3-6 ml was transferred to the siliconised bUjou bottles containing 0 4 ml buffered sodium citrate (31-3 g/l tri-sodium citrate, 50 g/l HEPES); 4-5 m/l was added to 0-5 ml of 9 g/l NaCl containing 1000 U/ml heparin and 1000 U/ml Trasylol (Bayer) and subsequently used for the measurement offibrinopeptide A. The remainder was taken into disodium edetic and (1 g/l) for white cell count and differential. The method used for measurement of whole blood procoagulant activity was based on that described by Dasmahapatra et al."7 As soon as possible after blood The reproducibility of the assay was assessed by performing replicate determinations (n = 10) on a normal blood sample, with and without endotoxin stimulation. The coefficients of variation for unstimulated and stimulated clotting times were 10-8% (range 246-347 seconds) and 15 4% (range 217-357 seconds), respectively.
Total white cell counts were determined electronically using a Coulter Counter (model Zn). Absolute monocyte counts were calculated from the total white cell counts and the percentage of monocytes observed in blood films stained by the Romanovsky method.
Plasma fibrinopeptide A concentrations were determined with a commercially available ELISA assay (Boehringer Diagnostics).
The siliconised glass tubes and the buffered citrate anticoagulant used in this study were tested with a commercially available chromogenic technique (Kabi Diagnostics) and found to be free of contaminating endotoxin.
Analysis of data was performed using the STATGRAPHICS statistical software system. The observations were not always normally distributed, and summary statistics were therefore expressed as medians and interquartile ranges. Differences between groups were assessed with the Mann-Whitney U test or the Kruskal-Wallis procedure for non-parametric data.
Results

WHOLE BLOOD PROCOAGULANT ACTIVITY
Without endotoxin
The median values, interquartile ranges (IQR), and total ranges of the clotting times for unstimulated samples in each subject group are shown in table 2. Unstimulated clotting times in the patient groups did not differ significantly from those of the normal control group, and there were no differences between Whole bloodprocoagulant activity in breast and colorectal cancer The colorectal tumours were classified after surgery according to the Dukes' staging system. There were no differences in clotting times (with or without endotoxin), percentage shortening, white cell counts, absolute monocyte counts and plasma fibrinopeptide A of patients with colorectal cancer subdivided into Dukes' stages A-C (table 6).
EFFECT OF AGE ON PROCOAGULANT ACTIVITY
The median ages and age ranges of each subject group are shown in table 1. All subject groups were signifi- cantly older than the normal controls and patients with benign breast disease (p < 0 001), although there was no difference between the ages of subjects with malignant and benign colorectal disease. Individual subject ages were poorly correlated with whole blood procoagulant activity expressed as percentage shortening of the clotting time (r = 0-147, p = 0 105, n = 122). Nevertheless, the median procoagulant activity of each group was significantly correlated with the median group age (r = 083, p < 0 05, n = 6).
Discussion
The shortening of the recalcification time of whole blood incubated with endotoxin is directly related to the increase in monocyte tissue factor synthesis. 16 Thus Dasmahapatra and coworkers assessed monocyte tissue factor activity in whole blood from patients with solid tumours, and suggested that this test might distinguish cancer patients from normal controls and those with benign disease.'7 To confirm these findings we measured monocyte tissue factor activity in whole blood from patients with breast and colorectal cancer and compared the results with histological staging, absolute monocyte counts, and plasma concentrations.
Dasmahapatra et al reported that the recalcification times of both stimulated and unstimulated whole blood from cancer patients were significantly shorter than normal.'" In the present study there were no differences in the unstimulated recalcification times, although the median recalcification time of both breast and colorectal cancer patients were significantly shorter than normal controls after addition of endotoxin. Even after endotoxin stimulation, however, the median recalcification times ofthe cancer patients were not different from the corresponding benign or surgical inpatient controls. Furthermore, the median stimulated recalcification time of the benign colorectal control group was also significantly shorter than that ofthe normal controls. As monocyte tissue factor generation may be increased in active Crohn's disease, however,'8 and colonic diverticula in the United Kingdom are common in persons over 60 years old,'9 concurrent inflammatory processes, such as diverticulitis, may account for this finding.
Although there were no differences in unstimulated or stimulated clotting times between benign and malignant groups, it was noteworthy that the stimulated clotting times were significantly shorter than the corresponding unstimulated values in the patients with cancer alone. Thus despite the lack of difference among subject groups, significant amounts of monocyte tissue factor induced by endotoxin were produced only in subjects with malignant disease.
Taken together, therefore, these data show only partial agreement with the earlier study."' Our inability to distinguish controls and cancer patients, however, may be partly due to the technical drawbacks of this method for assessing whole blood procoagulant activity. Firstly, unless contact activation is standardised, the whole blood clotting time20 has a very wide normal range. In the original study'7 absolute monocyte numbers were not determined, and monocytosis, which often accompanies malignant disease,24 may have contributed to the higher monocyte tissue factor activity in the cancer patients. In the present study, however, the absolute monocyte counts did not differ significantly among subject groups.
There were no significant differences in plasma fibrinopeptide A concentrations among any of the groups. The median values in the benign breast and normal control groups were normal (< 3 ng/ml), although those in the other four groups were slightly raised. Despite a previous report of a correlation between plasma fibrinopeptide A and monocyte tissue factor generation in cancer patients,'4 no relation between whole blood monocyte tissue factor and plasma fibrinopeptide A was apparent in the current study.
In agreement with an earlier report,25 there was no correlation between monocyte tissue factor concentrations and TN staging in patients with breast cancer. Because advanced breast cancer is treated palliatively, however, only those patients with early disease are admitted for surgery and were included in this study. Similarly, there were no significant differences in monocyte tissue factor concentrations among colorectal cancer patients classified according to Dukes' stage.
Monocyte tissue factor activity may increase with age,26 and, as patients with malignant disease are usually older than those with benign disorders, increased monocyte tissue factor expression in cancer may simply reflect this age difference. We found no correlation between whole blood monocyte tissue factor and age, however, although a significant correlation was noted between the median ages and monocyte tissue factor concentrations of the six subject groups.
In conclusion, the results of this study suggest that the whole blood recalcification time in cancer patients is more sensitive to bacterial endotoxin than in normal controls or patients with benign disease. In its present form, however, this test cannot be used to distinguish malignant and benign disease on an individual basis, although further studies, preferably with an improved method for measuring procoagulant activity in whole blood, are justified.
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